ArticleMolecular biology reports2025
Role of furin in the severity of COVID-19 infection via effects on miR-20b and miR-106a.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immuno-epigenetic paradigms in coronavirus infection.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince 2019, COVID-19 and its mutants have been among the fiercest epidemic viruses. Coronavirus is still affecting the world and will continue through its various mutants, the closest example of which is the XEC mutant. Vaccines are currently available to prevent coronavirus infections. However, the currently approved treatments after infection, especially for severely infected patients, are still limited, and they are not suitable for everyone. Many studies have investigated the ability of furin to repair coronavirus viral proteins, and other studies have shown how important miRNAs are for controlling gene expression. AIM OF WORK: This work aims to clarify the role of furin and the possibility of alleviating the burden of viral infection with COVID-19 and its mutations via effects on miR-20b and miR-106a. PATIENTS AND
methodsWe collected blood samples from 40 controls and 50 patients. Each patient provided approximately 3 ml of blood, which was separated for measuring furin by ELISA and extracting RNA for real-time PCR for the relative quantification of miRNAs.
resultsThe serum levels of Furin and miR-106 were considerably greater in the COVID-19 group than in the control group; however, the level of miR-20b was considerably greater in the control group than in the patients group.
conclusionThese data suggest that furin and miR-20b concentrations could be beneficial in therapeutic approaches against COVID-19.
Indexed as
Identifiers
40095093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.